Nevropram (Citalopram Hydrobromide)

Citalopram hydrobromide selectively blocks the serotonin transporter (SERT) on presynaptic neurons, preventing reuptake of serotonin from the synaptic cleft. By increasing extracellular serotonin levels, it amplifies serotonergic signaling throughout the brain, which contributes to mood elevation and anxiety reduction in the conditions for which it is prescribed.

The appropriate dose of Nevropram is individualized by the prescribing healthcare professional. Factors such as the patient’s age, severity of symptoms, liver function, and concomitant medications influence the selected dosage. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Citalopram’s pregnancy category is listed as unknown, and safety data are limited. Clinicians weigh potential benefits against possible risks before prescribing to pregnant or nursing women. If treatment is deemed necessary, the prescriber will monitor both mother and infant closely and discuss any concerns with the patient.

To request Nevropram, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nevropram (citalopram) is a highly selective SSRI with a relatively favorable side‑effect profile compared with some older agents. It has a lower affinity for other neurotransmitter receptors, which may reduce certain adverse effects such as weight gain. However, individual response varies, and clinicians choose an SSRI based on efficacy, tolerability, drug‑interaction potential, and patient history.

Nevropram tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity, which could affect tablet integrity.

Nevropram is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing and whether to maintain a consistent routine to help achieve stable blood levels.

The most serious risks include serotonin syndrome (characterized by agitation, fever, muscle rigidity), emergence of suicidal thoughts especially during early treatment, and cardiac effects such as QT‑interval prolongation. Patients should seek immediate medical attention if they experience any of these symptoms.

Nevropram should be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those who have taken an MAOI within the past 14 days. Patients with known hypersensitivity to citalopram or any component of the tablet, as well as those with certain cardiac conditions that predispose to QT prolongation, should not use this medication without specialist advice.